Fiasp Injection, Solution
Product Images NDC 0169-3201

Product Visual Gallery

This gallery contains 59 technical images submitted to the FDA as part of the official labeling for Fiasp (NDC 0169-3201). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novo Nordisk, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Image 01)

Chemical structure diagram of insulin aspart showing its A-chain and B-chain amino acid sequences. The diagram includes peptide bonds, disulfide bridges, and amino acid identities for each position in the chains.*

FDA Label Image

Figure 2 (Image 02)

This is a line graph depicting the insulin effect, measured in GIR (mg/kg*min), over time in minutes up to 420 minutes. The graph compares three dose levels of Fiasp insulin aspart injection: 0.1, 0.2, and 0.4 units/kg, shown as solid, dashed, and dotted lines respectively, demonstrating how insulin effect varies with dose and time.*

FDA Label Image

Figure 3 (Image 03)

A line graph depicting the insulin aspart concentration (pmol/L) over time (minutes) for Fiasp insulin injection. The graph shows concentration rising sharply to a peak around 50-60 minutes, then gradually declining towards 360 minutes, illustrating the pharmacokinetic profile of Fiasp.*

FDA Label Image

Fiasp Vial (Image 07)

Illustration of a vial container featuring a rubber stopper with a tamper-resistant cap, commonly used for injectable solutions such as insulin aspart injection.*

FDA Label Image

Vial Of Fiasp (Image 08)

An instructional illustration showing a hand holding a small vial or bottle, representing the handling of a medication container, likely for subcutaneous injection. This image suggests preparation or administration steps for an injection solution.*

FDA Label Image

Figure A And B (Pull off cap)

An instructional illustration showing two step-by-step drawings of hands manipulating a medical vial or pen device, likely demonstrating preparation or usage technique for a subcutaneous injection of Fiasp insulin aspart injection 100 units/mL by Novo Nordisk.*

FDA Label Image

Figure C (Hold syringe with needle pointing up)

An instructional illustration showing the process of preparing an injectable solution, specifically depicting hands holding a syringe and needle, with an arrow indicating the direction for attaching or detaching the needle cap.*

FDA Label Image

Figure D (Push needle through stopper.)

An instructional illustration showing how to prepare an injection by inserting a needle into a vial or cartridge, with one hand holding the vial and the other hand guiding the syringe needle. The image includes an arrow indicating the direction of needle insertion.*

FDA Label Image

Figure E (Push plunger all the way in.)

An instructional illustration showing how to use an injection device, depicting one hand holding a pen-like device and the other hand preparing or adjusting the cap or needle, with an arrow indicating the direction of movement.*

FDA Label Image

Figure F Pull The Plunger Down. (Image 13)

An instructional illustration showing a hand holding a vial upside down and another hand holding a syringe. An arrow indicates the syringe being inserted into the vial to draw the solution out. This likely demonstrates the step of withdrawing insulin aspart injection solution for subcutaneous administration.*

FDA Label Image

Figure G (Tap the syringe.)

An instructional diagram showing two hands preparing an injection. One hand holds an upright vial inverted over a syringe, while the other hand stabilizes the syringe. The image depicts the process of drawing medication from the vial into the syringe.*

FDA Label Image

Figure H (Slowly push the plunger.)

An instructional diagram showing a hand holding a syringe and attaching a needle cap. The smaller inset illustrates a close-up view of the needle cap being removed or attached. The diagram likely demonstrates a step in preparing an injection.*

FDA Label Image

Figure I (Pull the syringe out.)

An instructional diagram showing how to prepare a subcutaneous injection. The figure illustrates a hand holding a cap and pulling it off a vial or pen device, indicated by an arrow pointing upward to represent removal of the cap.*

FDA Label Image

Figure J (Choose injection site.)

An anatomical instructional diagram showing front and back views of a human body, with highlighted areas indicating common subcutaneous injection sites suitable for insulin administration, including the abdomen, thighs, and upper arms.*

FDA Label Image

Figure K (Insert the needle.)

Instructional illustration showing how to prepare an insulin injection, with one hand holding the area of injection and the other hand using a syringe to administer the injection subcutaneously.*

FDA Label Image

Figure L (Pull the needle out.)

Illustration showing a hand administering a subcutaneous injection with a syringe into the abdominal area, demonstrated by an arrow pointing to the injection site on the skin. This instructional diagram is associated with insulin injection use.*

FDA Label Image

Figure A (NovoFine needle components.)

An instructional illustration showing four parts of a NovoFine needle: outer needle cap, inner needle cap, needle, and paper tab. Each component is labeled and depicted separately for identification.*

FDA Label Image

Figure A (NovoFine Plus needle components.)

An instructional diagram labeled NovoFine Plus showing four components of a needle assembly: outer needle cap, inner needle cap, needle, and paper tab. The diagram visually identifies each part in sequence from left to right.*

FDA Label Image

Figure A (NovoTwist needle components.)

An instructional illustration showing components of a NovoTwist needle: outer needle cap, inner needle cap, needle, and paper tab. The diagram identifies each part separately, likely to aid in proper assembly or removal for injection use with Fiasp insulin aspart injection.*

FDA Label Image

Overview Of Fiasp Flextouch Pen (Image 23)

An illustrated diagram of a Fiasp FlexTouch insulin injection pen showing labeled parts: pen cap, insulin scale, insulin window, dose counter, dose selector, dose pointer, and dose button. The pen body is marked with the Fiasp brand and insulin aspart injection information, highlighting the key functional components for dose administration.*

FDA Label Image

Figure B (Image 24)

FDA Label Image

Figure C (Image 26)

An instructional illustration showing a close-up of both hands holding an insulin pen. One hand is grasping the pen while the other hand pulls off or attaches a component, likely the protective cap or needle cover, as part of preparing the injection device for use.*

FDA Label Image

Figure D (Image 27)

An instructional illustration labeled Figure C showing a hand holding a pen-like injection device with a capped needle end, likely demonstrating preparation or handling of the device for subcutaneous administration.*

FDA Label Image

Figure E (Image 28)

An instructional illustration showing two close-up views of hands twisting the caps on NovoFine and NovoTwist pen needles, demonstrating the correct technique for detaching needle covers, presumably related to Fiasp insulin aspart injection pen use.*

FDA Label Image

Figure F (Image 29)

An instructional illustration depicting two steps of vial preparation for injection. The left panel shows a vial being gently rolled or inverted, while the right panel shows a twisting action on the vial cap, likely part of the preparation or mixing process for the insulin aspart injection.*

FDA Label Image

Figure G (Image 30)

An instructional illustration showing a two-step process involving the attachment of a needle to a syringe or pen device. The first panel depicts an arrow indicating the removal of a protective cover from the needle. The second panel shows the needle being firmly screwed or attached to the device, guided by an arrow indicating rotational movement.*

FDA Label Image

Figure H (Image 31)

Instructional illustration showing a user removing the cap from an injection pen labeled NovoFine, NovoFine Plus, or NovoTwist, demonstrating preparation steps for subcutaneous insulin aspart injection administration.*

FDA Label Image

Figure I (Image 32)

Illustration showing a close-up of a person adjusting a dose selector on an insulin pen injector. The dial displays '02', indicating 2 units selected for injection. The image visually guides dose selection for insulin administration.*

FDA Label Image

Figure J (Image 33)

An instructional illustration depicting a hand holding a pen-like injection device with the thumb positioned on the top, showing the action of pressing or tapping the device. The image indicates motion lines to suggest the device is being shaken or tapped before use.*

FDA Label Image

Figure K (Image 34)

An instructional illustration showing a hand holding a Fiasp insulin aspart injection pen. The image highlights the step of priming or preparing the pen, indicated by an arrow pointing upward and an inset close-up of the pen's needle cap area.*

FDA Label Image

Figure L (Image 35)

An instructional illustration showing a person adjusting the dose selector on an injection pen for Fiasp (insulin aspart injection). The image demonstrates selecting doses of 5 units, with example close-ups of dialed doses showing 4 to 6 units and 22 to 24 units. The diagram highlights how to turn the dial up or down to choose a dose.*

FDA Label Image

Figure M (Image 36)

Illustration labeled Figure L showing a syringe with measurement markings, indicating an approximate 200 units of insulin solution left. The syringe is partially filled and designed for subcutaneous injection.*

FDA Label Image

Figure N (Image 37)

An illustration showing front and back views of a human torso and legs, indicating common subcutaneous injection sites for insulin aspart injection (Fiasp). The marked areas include the abdomen, front and outer sides of the thighs, and the upper outer part of the buttocks.*

FDA Label Image

Figure O (Image 38)

An instructional diagram showing a hand holding a pen-style injection device with the thumb pressing a top button. A downward arrow beneath the pen indicates the direction to apply pressure or the direction of injection.*

FDA Label Image

Figure P (Image 39)

An instructional illustration showing a hand holding a syringe for subcutaneous injection. The image indicates an injection angle with an arrow pointing downward toward the skin, emphasizing proper technique for injecting medication, likely representing insulin administration instructions.*

FDA Label Image

Figure Q (Image 40)

An instructional illustration depicting a hand holding an insulin pen device. A speech bubble instructs to count slowly from 1 to 6, indicating a step to be followed when using the device. The illustration appears to guide proper injection technique, possibly part of a patient information leaflet for Fiasp insulin aspart injection.*

FDA Label Image

Figure R (Image 41)

An instructional figure labeled as Figure Q, depicting an injection syringe held vertically with the needle pointing downward and an upward arrow above it, suggesting an action related to the syringe's position or operation.*

FDA Label Image

Figure S (Image 42)

An instructional illustration showing two steps for using the NovoFine and NovoTwist injection needles. The first panel demonstrates twisting the needle cap off, and the second panel shows pulling the cap straight upward to remove it.*

FDA Label Image

Figure T (Image 43)

An instructional diagram showing how to attach the cap to a syringe. It depicts a syringe with a needle and a cap positioned with arrows indicating the direction for attaching the cap to the needle.*

FDA Label Image

Flextouch Qr Code (Image 44)

An instructional illustration showing a hand holding a syringe cap and pulling it off in a twisting motion, likely demonstrating how to remove the cap from a syringe or injection device. The image is simple with arrows indicating the direction of movement.*

FDA Label Image

Fiasp Flextouch Pen (Image 57)

Fiasp FlexTouch injection pen label showing the proprietary name Fiasp and instructions to read before first use. The pen is depicted in blue with yellow and red accents. The label includes the Novo Nordisk logo at the bottom.*

FDA Label Image

Penfill (Overview)

An instructional diagram illustrating the components and assembly of needle caps for NovoFine, NovoFine Plus, and NovoTwist needles, and the parts of a PenFill cartridge compatible insulin delivery device, including pen cap, cartridge holder, threaded end for needle attachment, colored band, rubber plunger, dose pointer, dose counter, and dose selector/dose button.*

FDA Label Image

Figure B (Image 05)

An instructional illustration showing a hand holding a syringe with the threaded end visible. The diagram focuses on the proper orientation for attaching a component to the threaded end of the syringe, likely as part of preparation or administration instructions for the insulin aspart injection, Fiasp.*

FDA Label Image

Figure C (Image 06)

An instructional illustration showing hands preparing a syringe and vial for injection. One hand is holding the vial, and the other hand is pulling back the syringe plunger to draw the solution.*

FDA Label Image

Figure D (Image 25)

Instructional illustration for NovoFine and NovoTwist pen needles, showing how to remove the protective cap before use. The images depict finger positioning and cap removal techniques for these subcutaneous injection devices, used with insulin pen needles.*

FDA Label Image

Figure E (Image 47)

Instructional illustration showing step-by-step use of NovoFine and NovoTwist pen needles, likely demonstrating how to attach or handle these injection needles, commonly used with insulin pens for subcutaneous delivery.*

FDA Label Image

Figure F (Image 48)

Illustration showing proper technique for preparing an injection device, featuring how to connect components labeled as NovoFine or NovoTwist. The diagram displays gloved hands assembling injection parts step-by-step.*

FDA Label Image

Figure G (Image 49)

An illustration depicting a subcutaneous injection device or pen needle attached to a blue insulin pen, likely related to the administration of Fiasp insulin aspart injection.*

FDA Label Image

Figure H (Image 50)

An instructional diagram illustrating the dose selection mechanism for an insulin injection pen. It shows labeled components including the dose counter, dose selector, and dose pointer, with an example of 12 units selected on the dose display. The image guides users on setting the dose for subcutaneous insulin injection.*

FDA Label Image

Figure I (Image 51)

An instructional diagram showing recommended injection sites for subcutaneous administration. The diagram highlights the upper arms, abdomen, and upper thighs as preferred places to inject.*

FDA Label Image

Figure J (Image 52)

An instructional illustration showing a hand holding an injection pen, with a speech bubble indicating to count slowly from 1 to 6. The image likely demonstrates proper injection technique for a subcutaneous insulin aspart injection pen device.*

FDA Label Image

Figure K (Image 53)

An instructional diagram showing two arrows indicating the removal of a protective cap from a syringe or pen needle prior to injection, related to the use of Fiasp insulin aspart injection, solution, 100 IU/mL by Novo Nordisk.*

FDA Label Image

Figure L (Image 54)

An instructional illustration showing how to remove the cartridge holder from a pen device. The image depicts a hand gripping the pen and an arrow indicating the direction to pull the cartridge holder off. This is related to the Fiasp insulin aspart injection pen.*

FDA Label Image

Figure M (Image 55)

Instructional illustration showing a hand holding a syringe or pen device, with a visible arrow pointing to a section of the device. The image appears to guide the user on how to operate or prepare the injection device for use.*

FDA Label Image

Fiasp Pumpcart (Image 58)

An instructional illustration showing a vial of Fiasp insulin aspart injection, 100 units/mL. The image highlights and labels the vial's plunger and the white label band near the bottom of the vial.*

FDA Label Image

Fiasp Vial 8-0911-31-301-x (Image 45)

Fiasp (insulin aspart injection) 100 units/mL (U-100) injection, solution for subcutaneous or intravenous use. The label shows a 10 mL multi-dose vial, labeled for prescription use only, manufactured by Novo Nordisk. Storage instructions and a barcode are included on the carton.*

FDA Label Image

Fiasp (FlexTouch Carton 8-9505-31-301-X)

Fiasp PenFill insulin aspart injection 100 units/mL solution for subcutaneous use. The packaging indicates it is for single patient use only and compatible with Novo Nordisk cartridges. Contains 3 mL cartridges, 5 per package. Labeler is Novo Nordisk. The label includes usage directions, storage instructions, and contact information.*

FDA Label Image

Fiasp Penfill Carton 8-0910-31-301-x (Image 62)

Fiasp PenFill insulin aspart injection 100 units/mL solution in 3 mL cartridges. The packaging includes five cartridges per pack, labeled for single-patient use and subcutaneous administration. Manufactured and labeled by Novo Nordisk, the carton displays detailed storage instructions, usage warnings, and a barcode.*

FDA Label Image

Fiasp Pumpcart Carton (8-0912-31-301-1)

Box label for Fiasp (insulin aspart injection) PumpCart, 100 units/mL (U-100) subcutaneous injection, manufactured by Novo Nordisk. Contains 1.6 mL cartridges, 5 per package, for single-patient-use only. The label includes storage instructions, usage information, and regulatory details with a barcode and lot number.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.